📊 PYXS Key Takeaways
Is Pyxis Oncology, Inc. (PYXS) a Good Investment?
Pyxis Oncology faces critical financial distress with a cash burn rate of $63.5M annually against only $15.4M cash reserves, implying ~3 months of runway. The company generates minimal revenue ($13.9M, declining YoY) while operating at massive losses (-609% operating margin), indicating pre-commercial status with no path to profitability visible in current financials.
Why Buy Pyxis Oncology, Inc. Stock? PYXS Key Strengths
- Zero debt maintains balance sheet flexibility
- Positive stockholders equity of $53.4M provides cushion
- Short-term liquidity ratios healthy (3.41x current ratio)
PYXS Stock Risks: Pyxis Oncology, Inc. Investment Risks
- Critical cash runway of ~3 months at current burn rate threatens company viability
- Revenue declining 14.2% YoY with minimal absolute scale ($13.9M)
- Operating losses of $84.4M annually indicate unsustainable business model
- Imminent need for dilutive capital raise or major operational restructuring
- No evidence of clinical success, regulatory approvals, or near-term revenue inflection
Key Metrics to Watch
- Cash burn rate and cash runway remaining
- Clinical trial progress and pipeline advancement
- Subsequent financing activities and dilution impact
- Quarter-over-quarter revenue trends and customer acquisition
Pyxis Oncology, Inc. (PYXS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.41x current ratio provides a solid financial cushion.
PYXS Profit Margin, ROE & Profitability Analysis
PYXS vs Healthcare Sector: How Pyxis Oncology, Inc. Compares
How Pyxis Oncology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pyxis Oncology, Inc. Stock Overvalued? PYXS Valuation Analysis 2026
Based on fundamental analysis, Pyxis Oncology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pyxis Oncology, Inc. Balance Sheet: PYXS Debt, Cash & Liquidity
PYXS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pyxis Oncology, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.32 indicates the company is currently unprofitable.
PYXS Revenue Growth, EPS Growth & YoY Performance
PYXS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.8M | -$21.2M | $-0.35 |
| Q2 2025 | $2.8M | -$3.3M | $-0.29 |
| Q1 2025 | $16.1M | -$3.3M | $-0.06 |
| Q3 2024 | $16.1M | -$21.2M | $-0.35 |
| Q2 2024 | $16.1M | -$3.3M | $-0.29 |
| Q1 2024 | $16.1M | -$3.3M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pyxis Oncology, Inc. Dividends, Buybacks & Capital Allocation
PYXS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pyxis Oncology, Inc. (CIK: 0001782223)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PYXS
What is the AI rating for PYXS?
Pyxis Oncology, Inc. (PYXS) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PYXS's key strengths?
Claude: Zero debt maintains balance sheet flexibility. Positive stockholders equity of $53.4M provides cushion.
What are the risks of investing in PYXS?
Claude: Critical cash runway of ~3 months at current burn rate threatens company viability. Revenue declining 14.2% YoY with minimal absolute scale ($13.9M).
What is PYXS's revenue and growth?
Pyxis Oncology, Inc. reported revenue of $13.9M.
Does PYXS pay dividends?
Pyxis Oncology, Inc. does not currently pay dividends.
Where can I find PYXS SEC filings?
Official SEC filings for Pyxis Oncology, Inc. (CIK: 0001782223) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PYXS's EPS?
Pyxis Oncology, Inc. has a diluted EPS of $-1.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PYXS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Pyxis Oncology, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PYXS stock overvalued or undervalued?
Valuation metrics for PYXS: ROE of -149.1% (sector avg: 15%), net margin of -574.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PYXS stock in 2026?
Our dual AI analysis gives Pyxis Oncology, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PYXS's free cash flow?
Pyxis Oncology, Inc.'s operating cash flow is $-63.5M, with capital expenditures of $9.0K. FCF margin is -458.3%.
How does PYXS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -574.5% (avg: 12%), ROE -149.1% (avg: 15%), current ratio 3.41 (avg: 2).